Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EF-031
- Development stage
- Preclinical
- Lead developer
- Everfront Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EF-031 is an investigational oral small molecule drug being developed by Everfront Biotech for the treatment of solid tumors, including brain tumors and pancreatic cancer. Formulated as a softgel capsule, EF-031 is designed to cross the blood-brain barrier to target cancer cells and cancer stem cells within the central nervous system. It acts as a multi-target inhibitor of DNA methyltransferase 1 (DNMT1), mechanistic target of rapamycin (mTOR), programmed cell death 1 ligand 1 (PD-L1), tyrosine-protein kinase receptor UFO (Axl), and the CD44 intracellular domain (CD44ICD). By modulating these pathways, EF-031 aims to reduce chemotherapy resistance and enhance anti-tumor immune responses by converting "cold" tumors into "hot" tumors. It is intended to serve as a systemic therapy that can complement localized treatments like the Cerebraca Wafer.
02
Targets
CD44 (CD44 antigen)DNMT1 (DNA (cytosine-5)-methyltransferase 1)CD274 (Programmed cell death protein 1 ligand 1)AXL (AXL receptor tyrosine kinase)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on EF-031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EF-031.